LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Fan, Amy C"
  2. AU="Wu, Qihang"
  3. AU="Sakai"
  4. AU="I, Astigarraga"
  5. AU="Zopounidis, Constantin"
  6. AU=Dhanesha Nirav
  7. AU="Cejna, Manfred"
  8. AU="Bhavsar, Karan"
  9. AU="Machida, Haruhiko"
  10. AU="Rahaman, Md. Mizanur"
  11. AU="Henry, Carol"
  12. AU="St George-Hyslop, P"
  13. AU="Pham, Ngo Nghia"
  14. AU="Eeg-Olofsson, Karin Edebol"
  15. AU="Hosokawa, Yuri"
  16. AU="Christophi, Christopher"
  17. AU="Ren, Zhiyun"
  18. AU="Sabari, Benjamin R"
  19. AU="Sellal, Nabila"
  20. AU="Kamei, Yoshiki"
  21. AU="Htun Nyunt, Oo"
  22. AU="Lalonde, Donald H"
  23. AU=Olliaro Piero L AU=Olliaro Piero L
  24. AU="Fortney, J J"

Suchergebnis

Treffer 1 - 8 von insgesamt 8

Suchoptionen

  1. Artikel ; Online: Human ASXL1-Mutant Hematopoiesis Is Driven by a Truncated Protein Associated with Aberrant Deubiquitination of H2AK119.

    Köhnke, Thomas / Nuno, Kevin A / Alder, Catherine C / Gars, Eric J / Phan, Paul / Fan, Amy C / Majeti, Ravindra

    Blood cancer discovery

    2024  Band 5, Heft 3, Seite(n) 202–223

    Abstract: Mutations in additional sex combs like 1 (ASXL1) confer poor prognosis both in myeloid malignancies and in premalignant clonal hematopoiesis (CH). However, the mechanisms by which these mutations contribute to disease initiation remain unresolved, and ... ...

    Abstract Mutations in additional sex combs like 1 (ASXL1) confer poor prognosis both in myeloid malignancies and in premalignant clonal hematopoiesis (CH). However, the mechanisms by which these mutations contribute to disease initiation remain unresolved, and mutation-specific targeting has remained elusive. To address this, we developed a human disease model that recapitulates the disease trajectory from ASXL1-mutant CH to lethal myeloid malignancy. We demonstrate that mutations in ASXL1 lead to the expression of a functional, truncated protein and determine that truncated ASXL1 leads to global redistribution of the repressive chromatin mark H2AK119Ub, increased transposase-accessible chromatin, and activation of both myeloid and stem cell gene-expression programs. Finally, we demonstrate that H2AK119Ub levels are tied to truncated ASXL1 expression levels and leverage this observation to demonstrate that inhibition of the PRC1 complex might be an ASXL1-mutant-specific therapeutic vulnerability in both premalignant CH and myeloid malignancy.
    Significance: Mutant ASXL1 is a common driver of CH and myeloid malignancy. Using primary human HSPCs, we determine that truncated ASXL1 leads to redistribution of H2AK119Ub and may affect therapeutic vulnerability to PRC1 inhibition.
    Mesh-Begriff(e) Humans ; Repressor Proteins/genetics ; Repressor Proteins/metabolism ; Mutation ; Ubiquitination ; Histones/metabolism ; Histones/genetics ; Hematopoiesis/genetics ; Clonal Hematopoiesis/genetics
    Chemische Substanzen ASXL1 protein, human ; Repressor Proteins ; Histones
    Sprache Englisch
    Erscheinungsdatum 2024-02-13
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 3028898-8
    ISSN 2643-3249 ; 2643-3230
    ISSN (online) 2643-3249
    ISSN 2643-3230
    DOI 10.1158/2643-3230.BCD-23-0235
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: IDH1-Mutant Preleukemic Hematopoietic Stem Cells Can Be Eliminated by Inhibition of Oxidative Phosphorylation.

    Landberg, Niklas / Köhnke, Thomas / Feng, Yang / Nakauchi, Yusuke / Fan, Amy C / Linde, Miles H / Karigane, Daiki / Lim, Kelly / Sinha, Rahul / Malcovati, Luca / Thomas, Daniel / Majeti, Ravindra

    Blood cancer discovery

    2024  , Seite(n) OF1–OF18

    Abstract: Rare preleukemic hematopoietic stem cells (pHSC) harboring only the initiating mutations can be detected at the time of acute myeloid leukemia (AML) diagnosis. pHSCs are the origin of leukemia and a potential reservoir for relapse. Using primary human ... ...

    Abstract Rare preleukemic hematopoietic stem cells (pHSC) harboring only the initiating mutations can be detected at the time of acute myeloid leukemia (AML) diagnosis. pHSCs are the origin of leukemia and a potential reservoir for relapse. Using primary human samples and gene editing to model isocitrate dehydrogenase 1 (IDH1) mutant pHSCs, we show epigenetic, transcriptional, and metabolic differences between pHSCs and healthy hematopoietic stem cells (HSC). We confirm that IDH1-driven clonal hematopoiesis is associated with cytopenia, suggesting an inherent defect to fully reconstitute hematopoiesis. Despite giving rise to multilineage engraftment, IDH1-mutant pHSCs exhibited reduced proliferation, blocked differentiation, downregulation of MHC class II genes, and reprogramming of oxidative phosphorylation metabolism. Critically, inhibition of oxidative phosphorylation resulted in the complete eradication of IDH1-mutant pHSCs but not IDH2-mutant pHSCs or wild-type HSCs. Our results indicate that IDH1-mutant preleukemic clones can be targeted with complex I inhibitors, offering a potential strategy to prevent the development and relapse of leukemia.
    Significance: A high burden of pHSCs is associated with worse overall survival in AML. Using single-cell sequencing, metabolic assessment, and gene-edited human models, we find human pHSCs with IDH1 mutations to be metabolically vulnerable and sensitive to eradication by complex I inhibition. See related commentary by Steensma.
    Sprache Englisch
    Erscheinungsdatum 2024-01-23
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 3028898-8
    ISSN 2643-3249 ; 2643-3230
    ISSN (online) 2643-3249
    ISSN 2643-3230
    DOI 10.1158/2643-3230.BCD-23-0195
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: Niche-directed therapy in acute myeloid leukemia: optimization of stem cell competition for niche occupancy.

    Patel, Shyam A / Dalela, Disha / Fan, Amy C / Lloyd, Maxwell R / Zhang, Tian Y

    Leukemia & lymphoma

    2021  Band 63, Heft 1, Seite(n) 10–18

    Abstract: Acute myeloid leukemia (AML) is an aggressive malignancy of stem cell origin that contributes to significant morbidity and mortality. The long-term prognosis remains dismal given the high likelihood for primary refractory or relapsed disease. An ... ...

    Abstract Acute myeloid leukemia (AML) is an aggressive malignancy of stem cell origin that contributes to significant morbidity and mortality. The long-term prognosis remains dismal given the high likelihood for primary refractory or relapsed disease. An essential component of relapse is resurgence from the bone marrow. To date, the murine hematopoietic stem cell (HSC) niche has been clearly defined, but the human HSC niche is less well understood. The design of niche-based targeted therapies for AML must account for which cellular subsets compete for stem cell occupancy within respective bone marrow microenvironments. In this review, we highlight the principles of stem cell niche biology and discuss translational insights into the AML microenvironment as of 2021. Optimization of competition for niche occupancy is important for the elimination of measurable residual disease (MRD). Some of these novel therapeutics are in the pharmacologic pipeline for AML and may be especially useful in the setting of MRD.
    Mesh-Begriff(e) Animals ; Bone Marrow/pathology ; Cell Competition ; Hematopoietic Stem Cells ; Humans ; Leukemia, Myeloid, Acute/pathology ; Leukemia, Myeloid, Acute/therapy ; Mice ; Stem Cell Niche ; Tumor Microenvironment
    Sprache Englisch
    Erscheinungsdatum 2021-08-19
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, N.I.H., Extramural ; Review
    ZDB-ID 1042374-6
    ISSN 1029-2403 ; 1042-8194
    ISSN (online) 1029-2403
    ISSN 1042-8194
    DOI 10.1080/10428194.2021.1966779
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: Genome engineering with Cas9 and AAV repair templates generates frequent concatemeric insertions of viral vectors.

    Suchy, Fabian P / Karigane, Daiki / Nakauchi, Yusuke / Higuchi, Maimi / Zhang, Jinyu / Pekrun, Katja / Hsu, Ian / Fan, Amy C / Nishimura, Toshinobu / Charlesworth, Carsten T / Bhadury, Joydeep / Nishimura, Toshiya / Wilkinson, Adam C / Kay, Mark A / Majeti, Ravindra / Nakauchi, Hiromitsu

    Nature biotechnology

    2024  

    Abstract: CRISPR-Cas9 paired with adeno-associated virus serotype 6 (AAV6) is among the most efficient tools for producing targeted gene knockins. Here, we report that this system can lead to frequent concatemeric insertions of the viral vector genome at the ... ...

    Abstract CRISPR-Cas9 paired with adeno-associated virus serotype 6 (AAV6) is among the most efficient tools for producing targeted gene knockins. Here, we report that this system can lead to frequent concatemeric insertions of the viral vector genome at the target site that are difficult to detect. Such errors can cause adverse and unreliable phenotypes that are antithetical to the goal of precision genome engineering. The concatemeric knockins occurred regardless of locus, vector concentration, cell line or cell type, including human pluripotent and hematopoietic stem cells. Although these highly abundant errors were found in more than half of the edited cells, they could not be readily detected by common analytical methods. We describe strategies to detect and thoroughly characterize the concatemeric viral vector insertions, and we highlight analytical pitfalls that mask their prevalence. We then describe strategies to prevent the concatemeric inserts by cutting the vector genome after transduction. This approach is compatible with established gene editing pipelines, enabling robust genetic knockins that are safer, more reliable and more reproducible.
    Sprache Englisch
    Erscheinungsdatum 2024-04-08
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 1311932-1
    ISSN 1546-1696 ; 1087-0156
    ISSN (online) 1546-1696
    ISSN 1087-0156
    DOI 10.1038/s41587-024-02171-w
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel ; Online: RUNX1 loss renders hematopoietic and leukemic cells dependent on IL-3 and sensitive to JAK inhibition.

    Fan, Amy C / Nakauchi, Yusuke / Bai, Lawrence / Azizi, Armon / Nuno, Kevin A / Zhao, Feifei / Köhnke, Thomas / Karigane, Daiki / Cruz-Hernandez, David / Reinisch, Andreas / Khatri, Purvesh / Majeti, Ravindra

    The Journal of clinical investigation

    2023  Band 133, Heft 19

    Abstract: Disease-initiating mutations in the transcription factor RUNX1 occur as germline and somatic events that cause leukemias with particularly poor prognosis. However, the role of RUNX1 in leukemogenesis is not fully understood, and effective therapies for ... ...

    Abstract Disease-initiating mutations in the transcription factor RUNX1 occur as germline and somatic events that cause leukemias with particularly poor prognosis. However, the role of RUNX1 in leukemogenesis is not fully understood, and effective therapies for RUNX1-mutant leukemias remain elusive. Here, we used primary patient samples and a RUNX1-KO model in primary human hematopoietic cells to investigate how RUNX1 loss contributes to leukemic progression and to identify targetable vulnerabilities. Surprisingly, we found that RUNX1 loss decreased proliferative capacity and stem cell function. However, RUNX1-deficient cells selectively upregulated the IL-3 receptor. Exposure to IL-3, but not other JAK/STAT cytokines, rescued RUNX1-KO proliferative and competitive defects. Further, we demonstrated that RUNX1 loss repressed JAK/STAT signaling and rendered RUNX1-deficient cells sensitive to JAK inhibitors. Our study identifies a dependency of RUNX1-mutant leukemias on IL-3/JAK/STAT signaling, which may enable targeting of these aggressive blood cancers with existing agents.
    Mesh-Begriff(e) Humans ; Core Binding Factor Alpha 2 Subunit/genetics ; Gene Expression Regulation ; Interleukin-3/genetics ; Interleukin-3/pharmacology ; Leukemia/drug therapy ; Leukemia/genetics ; Signal Transduction
    Chemische Substanzen Core Binding Factor Alpha 2 Subunit ; Interleukin-3 ; RUNX1 protein, human
    Sprache Englisch
    Erscheinungsdatum 2023-10-02
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 3067-3
    ISSN 1558-8238 ; 0021-9738
    ISSN (online) 1558-8238
    ISSN 0021-9738
    DOI 10.1172/JCI167053
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  6. Artikel ; Online: IDH1-mutant preleukemic hematopoietic stem cells can be eliminated by inhibition of oxidative phosphorylation.

    Landberg, Niklas / Köhnke, Thomas / Feng, Yang / Nakauchi, Yusuke / Fan, Amy C / Linde, Miles H / Karigane, Daiki / Lim, Kelly / Sinha, Rahul / Malcovati, Luca / Thomas, Daniel / Majeti, Ravindra

    Blood cancer discovery

    2023  

    Abstract: Rare preleukemic hematopoietic stem cells (pHSCs) harboring only the initiating mutations can be detected at the time of AML diagnosis. pHSCs are the origin of leukemia and a potential reservoir for relapse. Using primary human samples and gene-editing ... ...

    Abstract Rare preleukemic hematopoietic stem cells (pHSCs) harboring only the initiating mutations can be detected at the time of AML diagnosis. pHSCs are the origin of leukemia and a potential reservoir for relapse. Using primary human samples and gene-editing to model isocitrate dehydrogenase 1 (IDH1) mutant pHSCs, we show epigenetic, transcriptional, and metabolic differences between pHSCs and healthy hematopoietic stem cells (HSCs). We confirm that IDH1 driven clonal hematopoiesis is associated with cytopenia, suggesting an inherent defect to fully reconstitute hematopoiesis. Despite giving rise to multilineage engraftment, IDH1-mutant pHSCs exhibited reduced proliferation, blocked differentiation, downregulation of MHC Class II genes, and reprogramming of oxidative phosphorylation metabolism. Critically, inhibition of oxidative phosphorylation resulted in complete eradication of IDH1-mutant pHSCs but not IDH2-mutant pHSCs or wildtype HSCs. Our results indicate that IDH1-mutant preleukemic clones can be targeted with complex I inhibitors, offering a potential strategy to prevent development and relapse of leukemia.
    Sprache Englisch
    Erscheinungsdatum 2023-12-13
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 3028898-8
    ISSN 2643-3249 ; 2643-3230
    ISSN (online) 2643-3249
    ISSN 2643-3230
    DOI 10.1158/2643-3230.BCD-23-0195
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  7. Artikel ; Online: Black In Immuno: harnessing social media and digital platforms to connect the dots.

    Babdor, Joel / Fan, Amy C / Wane, Madina / Mbiribindi, Berenice / Mobley, Alexis S / Noel, Justine C / Kouame, Elaine

    Nature reviews. Immunology

    2021  Band 21, Heft 12, Seite(n) 756–757

    Mesh-Begriff(e) Allergy and Immunology ; Blacks/psychology ; Humans ; Online Social Networking ; Research Personnel/organization & administration ; Research Personnel/psychology ; Social Media ; Social Support ; Surveys and Questionnaires
    Sprache Englisch
    Erscheinungsdatum 2021-10-29
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 2062776-2
    ISSN 1474-1741 ; 1474-1733
    ISSN (online) 1474-1741
    ISSN 1474-1733
    DOI 10.1038/s41577-021-00645-5
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  8. Artikel ; Online: Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy.

    Linde, Miles H / Fan, Amy C / Köhnke, Thomas / Trotman-Grant, Aaron C / Gurev, Sarah F / Phan, Paul / Zhao, Feifei / Haddock, Naomi L / Nuno, Kevin A / Gars, Eric J / Stafford, Melissa / Marshall, Payton L / Dove, Christopher G / Linde, Ian L / Landberg, Niklas / Miller, Lindsay P / Majzner, Robbie G / Zhang, Tian Yi / Majeti, Ravindra

    Cancer discovery

    2023  Band 13, Heft 5, Seite(n) 1164–1185

    Abstract: Therapeutic cancer vaccination seeks to elicit activation of tumor-reactive T cells capable of recognizing tumor-associated antigens (TAA) and eradicating malignant cells. Here, we present a cancer vaccination approach utilizing myeloid-lineage ... ...

    Abstract Therapeutic cancer vaccination seeks to elicit activation of tumor-reactive T cells capable of recognizing tumor-associated antigens (TAA) and eradicating malignant cells. Here, we present a cancer vaccination approach utilizing myeloid-lineage reprogramming to directly convert cancer cells into tumor-reprogrammed antigen-presenting cells (TR-APC). Using syngeneic murine leukemia models, we demonstrate that TR-APCs acquire both myeloid phenotype and function, process and present endogenous TAAs, and potently stimulate TAA-specific CD4+ and CD8+ T cells. In vivo TR-APC induction elicits clonal expansion of cancer-specific T cells, establishes cancer-specific immune memory, and ultimately promotes leukemia eradication. We further show that both hematologic cancers and solid tumors, including sarcomas and carcinomas, are amenable to myeloid-lineage reprogramming into TR-APCs. Finally, we demonstrate the clinical applicability of this approach by generating TR-APCs from primary clinical specimens and stimulating autologous patient-derived T cells. Thus, TR-APCs represent a cancer vaccination therapeutic strategy with broad implications for clinical immuno-oncology.
    Significance: Despite recent advances, the clinical benefit provided by cancer vaccination remains limited. We present a cancer vaccination approach leveraging myeloid-lineage reprogramming of cancer cells into APCs, which subsequently activate anticancer immunity through presentation of self-derived cancer antigens. Both hematologic and solid malignancies derive significant therapeutic benefit from reprogramming-based immunotherapy. This article is highlighted in the In This Issue feature, p. 1027.
    Mesh-Begriff(e) Animals ; Mice ; Antigen-Presenting Cells ; Neoplasms/therapy ; Antigens, Neoplasm ; Immunotherapy ; Leukemia ; Cancer Vaccines
    Chemische Substanzen Antigens, Neoplasm ; Cancer Vaccines
    Sprache Englisch
    Erscheinungsdatum 2023-03-15
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2625242-9
    ISSN 2159-8290 ; 2159-8274
    ISSN (online) 2159-8290
    ISSN 2159-8274
    DOI 10.1158/2159-8290.CD-21-0502
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang